A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that is still uncurable. The therapies used to treat the disease target immune activity, inhibit proteasome...

Descripción completa

Detalles Bibliográficos
Autores principales: Raimondi, Vincenzo, Iannozzi, Nicolas Thomas, Burroughs-Garcìa, Jessica, Toscani, Denise, Storti, Paola, Giuliani, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446161/
https://www.ncbi.nlm.nih.gov/pubmed/36071980
http://dx.doi.org/10.37349/etat.2022.00095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446161/
https://www.ncbi.nlm.nih.gov/pubmed/36071980
http://dx.doi.org/10.37349/etat.2022.00095

Ejemplares similares